News >

SM-88 Shows Encouraging Survival Trends in Advanced Pancreatic Cancer

Gina Columbus
Published: Tuesday, Jul 09, 2019

Allyson Ocean, MD

Allyson Ocean, MD

The oral modified dysfunctional tyrosine SM-88 demonstrated a median overall survival (OS) of 6.4 months in patients with advanced pancreatic cancer, according to updated results of the phase II TYME-88-Panc study that were presented at the 2019 World Congress on Gastrointestinal Cancer.1,2
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x